Vantictumab, formerly identified as OMP18R5, represents a novel monoclonal antibody designed to specifically inhibit OPN receptor 18R5. Such therapy is being studied by Amgen regarding possible uses in multiple bone https://www.targetmol.com/compound/vantictumab